Do analysts prefer CCM or ACON?

Aclarion has a consensus price target of $7.50, indicating a potential upside of 222.16%. Given Aclarion's stronger consensus rating and higher possible upside, analysts plainly believe Aclarion is more favorable than Concord Medical Services. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Concord Medical Services 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Aclarion 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has preferable valuation and earnings, CCM or ACON?

Aclarion has lower revenue, but higher earnings than Concord Medical Services. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Concord Medical Services $65.85M 0.32 -$13.27M N/A N/A Aclarion $80K 71.59 -$7.23M -$9.03 N/A

Does the media prefer CCM or ACON?

In the previous week, Aclarion had 3 more articles in the media than Concord Medical Services. MarketBeat recorded 4 mentions for Aclarion and 1 mentions for Concord Medical Services. Aclarion's average media sentiment score of 0.42 beat Concord Medical Services' score of 0.00 indicating that Aclarion is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Concord Medical Services 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Aclarion 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate MGRX or ACON?

Aclarion has a consensus target price of $7.50, suggesting a potential upside of 222.16%. Given Aclarion's stronger consensus rating and higher possible upside, analysts plainly believe Aclarion is more favorable than Mangoceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Mangoceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Aclarion 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Is MGRX or ACON more profitable?

Mangoceuticals has a net margin of -4,639.13% compared to Aclarion's net margin of -10,320.51%. Aclarion's return on equity of -54.41% beat Mangoceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Mangoceuticals -4,639.13% -112.00% -104.96% Aclarion -10,320.51% -54.41% -51.71%

Does the media refer more to MGRX or ACON?

In the previous week, Mangoceuticals had 4 more articles in the media than Aclarion. MarketBeat recorded 8 mentions for Mangoceuticals and 4 mentions for Aclarion. Mangoceuticals' average media sentiment score of 0.51 beat Aclarion's score of 0.42 indicating that Mangoceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Mangoceuticals 3 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Aclarion 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer ACON or BMGL?

Aclarion presently has a consensus price target of $7.50, suggesting a potential upside of 222.16%. Given Aclarion's stronger consensus rating and higher probable upside, equities analysts plainly believe Aclarion is more favorable than Basel Medical Group. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aclarion 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Basel Medical Group 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger valuation & earnings, ACON or BMGL?

Aclarion has higher earnings, but lower revenue than Basel Medical Group. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Aclarion $80K 71.59 -$7.23M -$9.03 N/A Basel Medical Group $8.90M 1.04 -$9.50M N/A N/A

Do analysts prefer BRTX or ACON?

Aclarion has a consensus target price of $7.50, suggesting a potential upside of 222.16%. Given Aclarion's stronger consensus rating and higher probable upside, analysts clearly believe Aclarion is more favorable than Biorestorative Therapies. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Biorestorative Therapies 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Aclarion 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Do analysts recommend NIVF or ACON?

Aclarion has a consensus price target of $7.50, indicating a potential upside of 222.16%. Given Aclarion's stronger consensus rating and higher possible upside, analysts plainly believe Aclarion is more favorable than NewGenIvf Group. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score NewGenIvf Group 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Aclarion 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has preferable valuation & earnings, NIVF or ACON?

NewGenIvf Group has higher revenue and earnings than Aclarion. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio NewGenIvf Group $4.73M 0.47 $9.88M N/A N/A Aclarion $80K 71.59 -$7.23M -$9.03 N/A

Does the media prefer NIVF or ACON?

In the previous week, Aclarion had 1 more articles in the media than NewGenIvf Group. MarketBeat recorded 4 mentions for Aclarion and 3 mentions for NewGenIvf Group. NewGenIvf Group's average media sentiment score of 0.43 beat Aclarion's score of 0.42 indicating that NewGenIvf Group is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment NewGenIvf Group 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Aclarion 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Aclarion (ACON) Competitors

$2.33 -0.03 (-1.36%)

As of 12:36 PM Eastern

Compare

ACON vs. CCM, MGRX, BMGL, BRTX, and NIVF

Should you buy Aclarion stock or one of its competitors? MarketBeat compares Aclarion with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Aclarion include Concord Medical Services (CCM), Mangoceuticals (MGRX), Basel Medical Group (BMGL), Biorestorative Therapies (BRTX), and NewGenIvf Group (NIVF).

How does Aclarion compare to Concord Medical Services?

Concord Medical Services (NYSE:CCM) and Aclarion (NASDAQ:ACON) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, risk, dividends, analyst recommendations, earnings, media sentiment, institutional ownership and profitability.

Aclarion has lower revenue, but higher earnings than Concord Medical Services.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Concord Medical Services	$65.85M	0.32	-$13.27M	N/A	N/A
Aclarion	$80K	71.59	-$7.23M	-$9.03	N/A

In the previous week, Aclarion had 3 more articles in the media than Concord Medical Services. MarketBeat recorded 4 mentions for Aclarion and 1 mentions for Concord Medical Services. Aclarion's average media sentiment score of 0.42 beat Concord Medical Services' score of 0.00 indicating that Aclarion is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Concord Medical Services	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Aclarion	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

7.5% of Aclarion shares are held by institutional investors. 46.5% of Concord Medical Services shares are held by company insiders. Comparatively, 0.0% of Aclarion shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Concord Medical Services has a net margin of 0.00% compared to Aclarion's net margin of -10,320.51%. Concord Medical Services' return on equity of 0.00% beat Aclarion's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Concord Medical Services	N/A	N/A	N/A
Aclarion	-10,320.51%	-54.41%	-51.71%

Aclarion has a consensus price target of $7.50, indicating a potential upside of 222.16%. Given Aclarion's stronger consensus rating and higher possible upside, analysts plainly believe Aclarion is more favorable than Concord Medical Services.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Concord Medical Services	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Aclarion	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Concord Medical Services has a beta of -0.97, indicating that its share price is 197% less volatile than the broader market. Comparatively, Aclarion has a beta of 1.22, indicating that its share price is 22% more volatile than the broader market.

Summary

Aclarion beats Concord Medical Services on 9 of the 14 factors compared between the two stocks.

How does Aclarion compare to Mangoceuticals?

Mangoceuticals (NASDAQ:MGRX) and Aclarion (NASDAQ:ACON) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, institutional ownership, analyst recommendations, profitability, dividends, risk, media sentiment and earnings.

In the previous week, Mangoceuticals had 4 more articles in the media than Aclarion. MarketBeat recorded 8 mentions for Mangoceuticals and 4 mentions for Aclarion. Mangoceuticals' average media sentiment score of 0.51 beat Aclarion's score of 0.42 indicating that Mangoceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Mangoceuticals	3 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Aclarion	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Aclarion has a consensus target price of $7.50, suggesting a potential upside of 222.16%. Given Aclarion's stronger consensus rating and higher possible upside, analysts plainly believe Aclarion is more favorable than Mangoceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mangoceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Aclarion	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Aclarion has lower revenue, but higher earnings than Mangoceuticals. Mangoceuticals is trading at a lower price-to-earnings ratio than Aclarion, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mangoceuticals	$460K	17.10	-$20.64M	-$1.49	N/A
Aclarion	$80K	71.59	-$7.23M	-$9.03	N/A

56.7% of Mangoceuticals shares are held by institutional investors. Comparatively, 7.5% of Aclarion shares are held by institutional investors. 16.0% of Mangoceuticals shares are held by insiders. Comparatively, 0.0% of Aclarion shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Mangoceuticals has a net margin of -4,639.13% compared to Aclarion's net margin of -10,320.51%. Aclarion's return on equity of -54.41% beat Mangoceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Mangoceuticals	-4,639.13%	-112.00%	-104.96%
Aclarion	-10,320.51%	-54.41%	-51.71%

Mangoceuticals has a beta of 2.09, suggesting that its stock price is 109% more volatile than the broader market. Comparatively, Aclarion has a beta of 1.22, suggesting that its stock price is 22% more volatile than the broader market.

Summary

Mangoceuticals and Aclarion tied by winning 8 of the 16 factors compared between the two stocks.

How does Aclarion compare to Basel Medical Group?

Aclarion (NASDAQ:ACON) and Basel Medical Group (NASDAQ:BMGL) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, media sentiment, analyst recommendations, institutional ownership, risk, dividends, earnings and profitability.

Aclarion presently has a consensus price target of $7.50, suggesting a potential upside of 222.16%. Given Aclarion's stronger consensus rating and higher probable upside, equities analysts plainly believe Aclarion is more favorable than Basel Medical Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aclarion	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Basel Medical Group	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Aclarion had 4 more articles in the media than Basel Medical Group. MarketBeat recorded 4 mentions for Aclarion and 0 mentions for Basel Medical Group. Aclarion's average media sentiment score of 0.42 beat Basel Medical Group's score of 0.00 indicating that Aclarion is being referred to more favorably in the media.

Company	Overall Sentiment
Aclarion	Neutral
Basel Medical Group	Neutral

7.5% of Aclarion shares are owned by institutional investors. 0.0% of Aclarion shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Aclarion has a beta of 1.22, meaning that its stock price is 22% more volatile than the broader market. Comparatively, Basel Medical Group has a beta of 0.24, meaning that its stock price is 76% less volatile than the broader market.

Aclarion has higher earnings, but lower revenue than Basel Medical Group.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aclarion	$80K	71.59	-$7.23M	-$9.03	N/A
Basel Medical Group	$8.90M	1.04	-$9.50M	N/A	N/A

Basel Medical Group has a net margin of 0.00% compared to Aclarion's net margin of -10,320.51%. Basel Medical Group's return on equity of 0.00% beat Aclarion's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aclarion	-10,320.51%	-54.41%	-51.71%
Basel Medical Group	N/A	N/A	N/A

Summary

Aclarion beats Basel Medical Group on 10 of the 14 factors compared between the two stocks.

How does Aclarion compare to Biorestorative Therapies?

Biorestorative Therapies (NASDAQ:BRTX) and Aclarion (NASDAQ:ACON) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, valuation, earnings, profitability and media sentiment.

Aclarion has a consensus target price of $7.50, suggesting a potential upside of 222.16%. Given Aclarion's stronger consensus rating and higher probable upside, analysts clearly believe Aclarion is more favorable than Biorestorative Therapies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biorestorative Therapies	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Aclarion	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Biorestorative Therapies has a net margin of -3,088.27% compared to Aclarion's net margin of -10,320.51%. Aclarion's return on equity of -54.41% beat Biorestorative Therapies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biorestorative Therapies	-3,088.27%	-508.42%	-230.94%
Aclarion	-10,320.51%	-54.41%	-51.71%

69.4% of Biorestorative Therapies shares are owned by institutional investors. Comparatively, 7.5% of Aclarion shares are owned by institutional investors. 13.6% of Biorestorative Therapies shares are owned by insiders. Comparatively, 0.0% of Aclarion shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Biorestorative Therapies has a beta of 0.79, meaning that its stock price is 21% less volatile than the broader market. Comparatively, Aclarion has a beta of 1.22, meaning that its stock price is 22% more volatile than the broader market.

Aclarion has lower revenue, but higher earnings than Biorestorative Therapies. Aclarion is trading at a lower price-to-earnings ratio than Biorestorative Therapies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biorestorative Therapies	$360K	15.08	-$14.24M	-$1.07	N/A
Aclarion	$80K	71.59	-$7.23M	-$9.03	N/A

In the previous week, Aclarion had 4 more articles in the media than Biorestorative Therapies. MarketBeat recorded 4 mentions for Aclarion and 0 mentions for Biorestorative Therapies. Aclarion's average media sentiment score of 0.42 beat Biorestorative Therapies' score of 0.00 indicating that Aclarion is being referred to more favorably in the news media.

Company	Overall Sentiment
Biorestorative Therapies	Neutral
Aclarion	Neutral

Summary

Aclarion beats Biorestorative Therapies on 10 of the 16 factors compared between the two stocks.

How does Aclarion compare to NewGenIvf Group?

NewGenIvf Group (NASDAQ:NIVF) and Aclarion (NASDAQ:ACON) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, institutional ownership, profitability, dividends, analyst recommendations, risk, media sentiment and valuation.

NewGenIvf Group has a net margin of 0.00% compared to Aclarion's net margin of -10,320.51%. NewGenIvf Group's return on equity of 0.00% beat Aclarion's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NewGenIvf Group	N/A	N/A	N/A
Aclarion	-10,320.51%	-54.41%	-51.71%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NewGenIvf Group	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Aclarion	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

66.2% of NewGenIvf Group shares are held by institutional investors. Comparatively, 7.5% of Aclarion shares are held by institutional investors. 31.8% of NewGenIvf Group shares are held by company insiders. Comparatively, 0.0% of Aclarion shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

NewGenIvf Group has higher revenue and earnings than Aclarion.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NewGenIvf Group	$4.73M	0.47	$9.88M	N/A	N/A
Aclarion	$80K	71.59	-$7.23M	-$9.03	N/A

In the previous week, Aclarion had 1 more articles in the media than NewGenIvf Group. MarketBeat recorded 4 mentions for Aclarion and 3 mentions for NewGenIvf Group. NewGenIvf Group's average media sentiment score of 0.43 beat Aclarion's score of 0.42 indicating that NewGenIvf Group is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
NewGenIvf Group	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Aclarion	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

NewGenIvf Group has a beta of 0.01, suggesting that its stock price is 99% less volatile than the broader market. Comparatively, Aclarion has a beta of 1.22, suggesting that its stock price is 22% more volatile than the broader market.

Summary

NewGenIvf Group beats Aclarion on 8 of the 14 factors compared between the two stocks.

Get Aclarion News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ACON and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ACON vs. The Competition

Export

Metric	Aclarion	Healthcare Technology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$5.68M	$1.44B	$6.81B	$12.94B
Dividend Yield	N/A	4.75%	2.60%	10.03%
P/E Ratio	-0.26	275.86	279.92	25.45
Price / Sales	71.59	64.03	647.84	115.11
Price / Cash	N/A	30.56	28.64	34.82
Price / Book	0.15	4.80	11.11	6.33
Net Income	-$7.23M	-$25.90M	$3.48B	$347.60M
7 Day Performance	9.30%	1.02%	2.04%	2.78%
1 Month Performance	-24.66%	-1.57%	-3.16%	-2.36%
1 Year Performance	-66.74%	-19.24%	63.65%	20.74%

Aclarion Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ACON Aclarion	3.9879 of 5 stars	$2.33 -1.4%	$7.50 +222.2%	-66.2%	$5.68M	$80K	N/A	7	News Coverage
CCM Concord Medical Services	0.6531 of 5 stars	$4.61 +2.2%	N/A	-25.0%	$19.58M	$65.85M	N/A	970	News Coverage Gap Down
MGRX Mangoceuticals	1.2639 of 5 stars	$0.56 +2.4%	N/A	-68.7%	$9.32M	$460K	N/A	3
BMGL Basel Medical Group	N/A	$6.38 +8.6%	N/A	-76.2%	$9.19M	$8.90M	N/A	36	Gap Down
BRTX Biorestorative Therapies	0.8503 of 5 stars	$0.27 -3.8%	N/A	-86.0%	$7.06M	$360K	N/A	7	Positive News Upcoming Earnings

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ACON) was last updated on 8/4/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Aclarion (ACON) Competitors

ACON vs. CCM, MGRX, BMGL, BRTX, and NIVF

How does Aclarion compare to Concord Medical Services?

Summary

How does Aclarion compare to Mangoceuticals?

Summary

How does Aclarion compare to Basel Medical Group?

Summary

How does Aclarion compare to Biorestorative Therapies?

Summary

How does Aclarion compare to NewGenIvf Group?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ACON vs. The Competition

Aclarion Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Aclarion (ACON) Competitors

ACON vs. CCM, MGRX, BMGL, BRTX, and NIVF

How does Aclarion compare to Concord Medical Services?

Which has preferable valuation and earnings, CCM or ACON?

Does the media prefer CCM or ACON?

Do insiders & institutionals hold more shares of CCM or ACON?

Is CCM or ACON more profitable?

Do analysts prefer CCM or ACON?

Which has more volatility and risk, CCM or ACON?

Summary

How does Aclarion compare to Mangoceuticals?

Does the media refer more to MGRX or ACON?

Do analysts rate MGRX or ACON?

Which has stronger earnings and valuation, MGRX or ACON?

Do institutionals and insiders hold more shares of MGRX or ACON?

Is MGRX or ACON more profitable?

Which has more risk and volatility, MGRX or ACON?

Summary

How does Aclarion compare to Basel Medical Group?

Do analysts prefer ACON or BMGL?

Does the media refer more to ACON or BMGL?

Do institutionals & insiders hold more shares of ACON or BMGL?

Which has more risk and volatility, ACON or BMGL?

Which has stronger valuation & earnings, ACON or BMGL?

Is ACON or BMGL more profitable?

Summary

How does Aclarion compare to Biorestorative Therapies?

Do analysts prefer BRTX or ACON?

Is BRTX or ACON more profitable?

Do institutionals and insiders hold more shares of BRTX or ACON?

Which has more volatility and risk, BRTX or ACON?

Which has better earnings and valuation, BRTX or ACON?

Does the media refer more to BRTX or ACON?

Summary

How does Aclarion compare to NewGenIvf Group?

Is NIVF or ACON more profitable?

Do analysts recommend NIVF or ACON?

Do insiders and institutionals hold more shares of NIVF or ACON?

Which has preferable valuation & earnings, NIVF or ACON?

Does the media prefer NIVF or ACON?

Which has more risk and volatility, NIVF or ACON?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ACON vs. The Competition

Aclarion Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools